Assessment of apolipoprotein B (apoB) levels does not seem to improve cardiovascular disease (CVD) risk prediction over low-density lipoprotein cholesterol (LDL) and non-high-density lipoprotein ...
Non-HDL-C as a CHD Risk Marker & On-treatment Guide to Therapy One means of examining non-HDL-C as a marker of atherosclerosis is to assess its value in postmortem atherosclerotic lesions. The ...
Clin Lipidology. 2010;5(4):457-464. Plasma LDL-C is used as a surrogate for the estimation of risk for the development of ASCVD. A true clinical end point, such as the incidence of ASCVD, would have ...
Hyperlipidemia is a risk factor for various cardiovascular and metabolic disorders. Overproduction of lipoproteins, a process that is dependent on microsomal triglyceride transfer protein (MTP), can ...
Scientists at the Medical University of South Carolina (MUSC) have found that a class of heart failure drugs might decrease low-density lipoprotein (LDL) cholesterol levels in patients who do not ...
Cardiac glycosides reduce a precursor of LDL cholesterol in a drug screen of statin-resistant hypercholesterolemia, new research concludes. A large meta-analysis of medical records revealed that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results